4D Molecular Therapeutics (Nasdaq: FDMT) granted a total of 229,700 restricted stock units to 20 new non-executive hires across three awards in 2026 under its Employment Inducement Award Plan. The grants occurred on February 10, April 14, and July 14, as part of Nasdaq-compliant inducement awards.
4D Molecular Therapeutics said 4D-150 is in Phase 3 for wet AMD and nearing Phase 3 in diabetic macular edema. The company reported rapid enrollment, 18-month treatment burden reductions and favorable safety data.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05930561 |
4D-150 in Patients With Diabetic Macular Edema |
ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT05248230 |
4D-710 in Adult Patients With Cystic Fibrosis |
RECRUITING | PHASE2 |
| NCT05197270 |
4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration |
RECRUITING | PHASE1/PHASE2 |
